On July 16, 2026, Kilitch Healthcare India announced the successful commissioning of a 1.25 MW rooftop solar project at its manufacturing facility in Talegaon, Dindori, Maharashtra. Developed by Polaris Renewable Solutions and commissioned in June 2026, the installation is designed to provide 1.25 MWp of direct current (DC) capacity while utilizing 1 MW of alternating current (AC) inverter capacity. The project is expected to offset 35% of the facility’s total power consumption, supporting the energy-intensive requirements of pharmaceutical manufacturing.
Financial and Operational Impact Analysis
The project represents a capital investment of ₹40 million and targets a strategic reduction in the facility’s high operational energy overheads. Prior to the installation, the Talegaon site incurred monthly electricity expenditures ranging between ₹3 million and ₹3.4 million. These high costs are driven by the continuous 24/7 nature of pharmaceutical production, where sterile injectable and formulation lines require constant HVAC operation, air handling units (AHUs), and cleanroom conditioning to maintain strict environmental standards.
The installation operates under a net metering arrangement for captive consumption. Key financial and operational benchmarks are summarized in the table below:
Project Financial & Operational Metrics
| Parameter | Data Point |
| Total Investment | ₹40 million |
| Annual Estimated Savings | ₹15 million |
| Monthly Estimated Savings | ₹1.25 million |
| Pre-installation Monthly Electricity Expenditure | ₹3 million to ₹3.4 million |
| Expected Payback Period | Less than three years |
| Power Offset Percentage | 35% of facility consumption |
Technical Specifications and Project Scope
The installation incorporates high-performance solar technology and engineering solutions tailored for the pharmaceutical environment. The technical configuration consists of the following components and benchmarks:
- Total Capacity: 1.25 MWp (DC) / 1 MW (AC).
- Solar Modules: Axitec Energy 600 Wp TOPCon modules.
- Inverters: Sungrow inverters (totaling 1 MW).
- Generation Benchmarks: Minimum guaranteed 150,000 units per month (approximately 5,000 units per day).
A primary engineering priority during execution was the implementation of a non-invasive mounting system. Polaris Renewable Solutions designed the system to avoid roof penetrations, thereby preserving the existing roof structure. In the context of pharmaceutical manufacturing, this non-invasive approach is critical to preventing potential leaks or external contamination that could compromise the integrity of the sterile manufacturing zones located beneath the roof. Additionally, the electrical layout was engineered to minimize both DC and AC power losses to maximize energy transmission efficiency to the facility’s internal grid.
Corporate Context and Strategic Outlook
Kilitch Healthcare India is a Mumbai-based pharmaceutical manufacturer specializing in sterile injectables (liquid and powder), ophthalmic and nasal formulations, prefilled syringes, and swab sticks. These manufacturing processes are notably energy-intensive, requiring precise temperature, pressure, and sterilization controls that operate without interruption.
According to company statements, Kilitch Healthcare is currently evaluating further investments in renewable energy to optimize power usage. This includes the potential integration of battery energy storage systems (BESS) to complement the solar project. The inclusion of BESS is being considered to mitigate the inherent intermittency of solar generation, ensuring a more stable and reliable power supply for the facility’s sensitive manufacturing equipment. The company reports that these initiatives are part of a broader commitment to securing judicious use of resources and long-term cost stability.
Official Sources: Kilitch Drugs (India) Ltd.
- Kilitch Drugs (India) Ltd. – Corporate Manufacturing Infrastructure & Facilities
Official company website detailing manufacturing locations and facility specifications.
Link: https://kilitch.com/infrastructure/ - Kilitch Drugs (India) Ltd. – National Stock Exchange (NSE) Regulatory Filing
Official disclosure of Board Meeting outcomes and Audited Financial Results for the year ended March 31, 2026.
Link: https://www.nseindia.com/ (Search Symbol: KILITCH)
Leave a Comment